|Trade names||Vantin, others|
|Other names||Cefpodoxime proxetil|
|Protein binding||21% to 29%|
|Metabolism||Negligible. Cefpodoxime proxetil is metabolized to cefpodoxime by the liver|
|Elimination half-life||2 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||427.45 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Cefpodoxime is an oral, third-generation cephalosporin antibiotic. It is active against most Gram-positive and Gram-negative organisms. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Currently, it is only marketed as generic preparations in the US, according to the FDA Orange Book. It is commonly used to treat acute otitis media, pharyngitis, sinusitis, and gonorrhea. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment.
Cefpodoxime inhibits cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis in cell walls. It has well established pharmacokinetic profile with absorption of 50%. It is indicated in community acquired pneumonia, uncomplicated skin and skin structure infections, and uncomplicated urinary tract infections.
It was patented in 1980 and approved for medical use in 1989.
Spectrum of bacterial susceptibility and resistance
Cefpodoxime has been used to fight pathogenic bacteria responsible for causing gonorrhoea, tonsillitis, pneumonia, and bronchitis. Representative pathogenic genera include Streptococcus, Haemophilus, and Neisseria. The following represents MIC susceptibility data for a few medically significant microorganisms.
- Haemophilus influenzae: ≤0.03 – 1 μg/ml
- Neisseria gonorrhoeae: 0.004 – 0.06 μg/ml
- Streptococcus pyogenes: ≤0.004 – 2 μg/ml
Toraxim (by Delta Pharma Ltd. Bangladesh)
Trucef (by Renata Limited, Bangladesh)
Tricef (by Alkaloid Skopje, North Macedonia)
MAPDOX-CV: Cefpodoxime and Clavulanic acid combination
MONOTAX O (Cefpodoxime)/ MONOTAX CV (Cefpodoxime and Clavulanic acid combination) (by Zydus Healthcare Ltd.)
POSTPOD-50 (Cefpodoxime 50mg/5ml) (by Laafon Galaxy Pharmaceuticals)
- Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 495. ISBN 9783527607495.
- "Cefpodoxime, Free Acid Susceptibility and Minimum Inhibitory Concentration (MIC) Data" (PDF).
- "Pharmaceuticals Manufacturer, Marketer, Pharmaceutical Manufacturing Company India". www.finecurepharma.com. Retrieved 2019-05-26.
- "Anti Biotics and Anti Bacterial". Finecurepharmaceuticalsltd. Archived from the original on 2012-03-06. Retrieved 2012-03-27.
- "Vantin – Drugs.com". www.drugs.com. Retrieved 2019-05-02.
- "Orelox - Drugs.com". www.drugs.com. Retrieved 2015-11-28.
- "Postpod dry syrup". Laafon Galaxy Pharmaceuticals Company in Karnal. Retrieved 2020-09-16.
- CID 6526396 from PubChem – cefpodoxime proxetil
- Vantin Tablets and Oral Suspension Torpod (Torrent) Full U.S. Prescribing Information (from manufacturer's website)
- Simplicef (from manufacturer's website)